Clinical trials: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Respiratory Syncytial Virus (RSV)
Burden of Respiratory Syncytial Virus (RSV) in Children in Sweden (BRICS): A Retrospective Study in Sweden
Primary Objective: -Estimate the hospital-associated healthcare resource use (HCRU), and associated costs, of RSV infection in children in comparison to the non-RSV control cohort (general population) and patients with rhinovirus…
- Trial name
- NCT05622331
- Volunteers
- 1,100,000 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infections
Music Therapy With Intubated and Sedated Pediatric Patients
The study is a randomized controlled trial of pediatric patients ages birth to two years of age who are mechanically ventilated and sedated as a result of a respiratory virus.
- Trial name
- NCT03629145
- Testing
- Live Music Therapy, Recorded Music Therapy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Children's Healthcare of Atlanta
Respiratory Syncytial Virus Infections
Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of different formulations of a single intramuscular dose of GSK Biologicals' investigational RSV vaccine, in healthy, non-pregnant women aged…
- Trial name
- NCT02360475
- Testing
- RSV vaccine GSK3003895A (formulation 1), RSV vaccine GSK3003898A (formulation 2), RSV vaccine GSK3003899A (formulation 3)
- Where
- 12 sites in United States, Australia and 2 more
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study
PC786 is a new medicine being developed for treatment of respiratory syncytial virus. The main purpose of this study is to evaluate the antiviral activity of PC786 in healthy adults infected with RSV virus in a viral challenge…
- Trial name
- NCT03382431
- Testing
- PC786
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Pulmocide Ltd
Respiratory Syncytial Virus Infections
Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.
The primary objective of the phase I trial is to evaluate the safety and tolerability of different doses of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) in adults aged 18 years and older, with the…
- Trial name
- NCT07582796
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant)
- Where
- China
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV)
Transplacental Transmission of RSV (TTRSV)
Aim 1: To study transplacental transmission of Respiratory Syncytial Virus (RSV) and how this is moderated by other maternal infections during pregnancy Aim 2: To test maternal blood for presence of RSV-specific immunoglobulins…
- Conditions
- SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
- Trial name
- NCT05443607
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Tulane University
Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
The purpose of this study is to provide critical information on the safety, reactogenicity and immunogenicity profile of the investigational recombinant chimpanzee adenovirus Type 155-vectored RSV (ChAd155-RSV) vaccine in infants…
- Trial name
- NCT03636906
- Testing
- RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine
- Where
- 37 sites in United States, Brazil and 11 more
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
Safety Study of Oral BTA9881 to Treat RSV Infection
This is a placebo-controlled, double-blind, randomised, single dose escalation Phase I clinical trial to determine the safety and tolerability of BTA9881 administered orally to healthy subjects
- Trial name
- NCT00504907
- Testing
- BTA9881
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Drug Safety, Respiratory Syncytial Virus Infections
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
The purpose of this study is to determine the range of single inhaled doses of a new dry powder product, MDT-637, that are safe and well-tolerated.
- Trial name
- NCT01355016
- Testing
- MDT-637
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MicroDose Therapeutx, Inc
Respiratory Syncytial Virus Infections
Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children
Human respiratory syncytial virus (RSV) is a common cause of upper respiratory tract illnesses as well as more severe lower respiratory illnesses, including bronchiolitis and pneumonia.
- Trial name
- NCT01459198
- Testing
- RSV MEDI ΔM2-2 vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bronchiolitis
Studying Innate Immune Responses in Infants With Bronchiolitis
This study aims to establish whether impaired innate immune responses are associated with severity of Respiratory syncytial virus (RSV) infection.
- Trial name
- NCT01159795
- Where
- United Kingdom
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Acute Respiratory Tract Infections
Effects of Nasal-spraying LiveSpo Navax in Treatment of Acute Respiratory Infections in Children
Rationals: Infection with the Respiratory Syncytial Virus (RSV) is one of the most common causes of respiratory tract diseases. However, treatment for pediatric RSV infection remains supportive to prevent co-infection bacteria…
- Trial name
- NCT05164692
- Testing
- LiveSpo Navax, 0.9% NaCl physiological saline
- Where
- Vietnam
- Volunteers
- 100 people
- Sponsor
- National Children's Hospital, Vietnam
Respiratory Synctial Virus
A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age
This is a randomized, observer-blind, irrelevant comparator-controlled trial in male and female subjects ≥24 months of age and <72 months of age.
- Trial name
- NCT02296463
- Testing
- RSV F Vaccine with adjuvant (0.5mL injection), RSV F Vaccine (0.5mL injection), Hepatitis A Vaccine (0.5mL injection)
- Where
- 4 sites in Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novavax
Respiratory Syncytial Virus Infections
Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)
The purpose of this study is to evaluate the effect of JNJ-53718678 on the development of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTIs) in adult hematopoietic stem cell transplant (HSCT) recipients…
- Trial name
- FREESIA (NCT04056611)
- Testing
- JNJ-53718678 250 mg, JNJ-53718678 125 mg
- Where
- 69 sites in United States, Argentina and 15 more
- Volunteers
- 3 people
- Sponsor
- Janssen Sciences Ireland UC
Respiratory Syncytial Virus Prevention
A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants
The purpose of the study is to evaluate the efficacy of study vaccine in the prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-confirmed RSV mediated- lower Respiratory Tract Disease (LRTD) over one RSV…
- Trial name
- NCT05242432
- Testing
- Ad26/protein preF RSV Vaccine
- Where
- 30 sites in Japan
- Volunteers
- 2,192 people
- Sponsor
- Janssen Pharmaceutical K.K.
Respiratory Syncytial Virus
A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age
The purpose of this study is to assess the incidence and associated healthcare utilization of RSV-associated, suspected LRTI in a general population of infants from birth up to 2 years of age, and also to assess the accuracy of a…
- Trial name
- NCT01995175
- Testing
- Nasal swab sampling, Blood sampling, Diary cards
- Where
- 23 sites in United States, Argentina and 6 more
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
RSV Infection, Respiratory Syncytial Virus Infections
RESCEU Study, Defining the Burden of Disease of RSV in Older Adults
The REspiratory Syncytial virus Consortium in EUrope (RESCEU) is an Innovative Medicine Initiative (IMI) funded by the EU under the H2020 framework to define and understand the burden of disease caused by human respiratory…
- Conditions
- RSV Infection, Respiratory Syncytial Virus Infections, Bronchiolitis
- Trial name
- NCT03621930
- Where
- 3 sites in Belgium, Netherlands and 1 more
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Respiratory Syncytial Virus Infections
Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524
MEDI-524 given for up to 5 doses at 3 and 15 mg/kg to high-risk children appeared to be safe and well tolerated.
- Trial name
- NCT00192478
- Testing
- Medi-524
- Where
- 3 sites in Argentina, Chile
- Volunteers
- 217 people
- Sponsor
- MedImmune LLC
Respiratory Syncytial Virus Infections
A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants
The purpose of this clinical trial is to learn about the safety, effects, and tolerability of the study medicine (sisunatovir). This study is looking for healthy adult participants who meet the following criteria: 1.
- Trial name
- NCT05873764
- Testing
- 200 mg RV521/78 µCi [ 14C]-RV521.
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infections
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
This was a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and symptoms of URTI.
- Trial name
- RSVTx (NCT04633187)
- Testing
- EDP-938
- Where
- 64 sites in United States, Argentina and 17 more
- Volunteers
- 9 people
- Sponsor
- Enanta Pharmaceuticals, Inc